Genetic Testing for APOL1 in Adults With Hypertension
JAMA Network Open · 2026
DOI: 10.1001/jamanetworkopen.2026.0528 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2026. Verfasst von Michael T Eadon und 35 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis. Hauptthemen laut MEDLINE: Apolipoprotein L1, Hypertension, Renal Insufficiency, Chronic, Genetic Testing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHGRI NIH HHS.
Abstract (Originalsprache)
Importance Apolipoprotein L1 locus ( APOL1 ) high-risk alleles are associated with incidence of chronic kidney disease (CKD) among people with African ancestry. Few studies have examined the effect of genetic return of results on blood pressure (BP) management and control.
Objective
To determine whether providing APOL1 high-risk genotype results to people with hypertension and their clinicians would reduce systolic BP (SBP) and improve CKD screening and diagnosis. Design, Setting, and Participants From July 1, 2020, to September 30, 2023, adults aged 18 to 70 years with hypertension and self-reported African ancestry were enrolled at 14 institutions and 54 clinical sites across the US. Eligible patients either (1) lacked diagnoses of diabetes and CKD or (2) had a diagnosis of CKD with or without diabetes.
Interventions
Participants were randomized to receive APOL1 genotype results immediately (intervention) or 6 months after enrollment (control). Clinical decision support encouraged appropriate CKD screening, diagnosis, and antihypertensive therapy. Main Outcomes and Measures The primary outcome was change in SBP in individuals with APOL1 high-risk allelles at 3 months, assessed in a modified intention-to-treat analysis. Prespecified per-protocol subgroup analyses included those with uncontrolled BP (baseline SBP ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg), uncontrolled BP while receiving antihypertensive therapy, and CKD at enrollment. Secondary outcomes included urine microalbumin screening and new CKD diagnoses.
Results
Of 6754 individuals recruited (mean [SD] age, 55.3 [10.3] years; 4310 women [63.8%]), 954 (14.1%; mean [SD] age, 54.9 [10.0] years; 600 women [62.9%]) had 2 APOL1 risk alleles. At 3 months, there was no difference in SBP between the intervention and control groups (between-group difference, −0.3 mm Hg [95% CI, −2.7 to 2.1 mm Hg]). Among 377 individuals with uncontrolled BP, the mean SBP change was −4.1 mm Hg (95% CI, −7.7 to −0.5 mm Hg) more in the intervention group than the control group ( P = .004). SBP improvement was also observed for the intervention in the subgroup of patients with uncontrolled BP receiving antihypertensive therapy (SPB difference, −4.3 mm Hg [95% CI −8.0 to −0.5 mm Hg]; P = .004), but not the CKD subgroup (SPB difference, 0.8 mm Hg [95% CI, −3.0 to 4.5 mm Hg]). Provision of APOL1 genotype led to increased urine microalbumin screening (between-group difference, 17.3% [95% CI, 9.6%-24.9%]; P < .001) and CKD diagnoses (between-group difference, 5.7% [95% CI, 2.2%-9.3%]; P = .002) at 6 months. Conclusions and Relevance Provision of APOL1 genotype high-risk results to participants and clinicians was not associated with SBP reduction overall. Among the subset of patients with uncontrolled BP, the intervention group had a significant SBP reduction. APOL1 disclosure also increased the rate of CKD screening and diagnosis. Effects of reporting APOL1 genotype merit further investigation among those with uncontrolled BP. Trial Registration ClinicalTrials.gov Identifier: NCT04191824
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis.
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis.
- Division of Nephrology & Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
- Barbara T. Murphy Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.
Förderung
- NIDDK NIH HHS
- NHGRI NIH HHS
Zitieren
APA
Eadon, M. T., Cavanaugh, K. L., She, L., Steen-Burrell, K. A., Mohottige, D., Nadkarni, G. N., Kitzman, H., Chakraborty, H., Empey, P. E., Limdi, N. A., Singh, R., Beasley, C. M., Parker, A. S., Cicali, E. J., Ramos, M. A., Clermont, S., Dodgen, L., Elwood, E. N., Robinson, M., …, & Implementing Genomics in Practice (IGNITE) Pragmatic Trials Network (2026). Genetic Testing for APOL1 in Adults With Hypertension. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.0528
Vancouver
Eadon MT, Cavanaugh KL, She L, Steen-Burrell KA, Mohottige D, Nadkarni GN, et al. Genetic Testing for APOL1 in Adults With Hypertension. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.0528
BibTeX
@article{Eadon2026,
author = {Eadon, Michael T and Cavanaugh, Kerri L and She, Lilin and Steen-Burrell, Kady-Ann and Mohottige, Dinushika and Nadkarni, Girish N and Kitzman, Heather and Chakraborty, Hrishikesh and Empey, Philip E and Limdi, Nita A and Singh, Rajbir and Beasley, Cherry Maynor and Parker, Alexander S and Cicali, Emily J and Ramos, Michelle A and Clermont, Sabrina and Dodgen, Leilani and Elwood, Erica N and Robinson, Mimsie and Umeukeje, Ebele M and Garcia Ortega, Abraham and Shroff, Nandini and Rosenman, Marc B and Nguyen, Khoa A and Volpi, Simona and Rider, Renee and Dexter, Paul R and Skaar, Todd C and Peterson, Josh F and Cavallari, Larisa H and Johnson, Julie A and Wyatt, Christina M and Orlando, Lori A and Cooper-DeHoff, Rhonda M and Horowitz, Carol R and Implementing Genomics in Practice (IGNITE) Pragmatic Trials Network, Implementing Genomics in Practice (IGNITE) Pragmatic Trials Network},
title = {Genetic Testing for APOL1 in Adults With Hypertension},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.0528}
}
EUVIMED